Viemed Announces Acquisition of Majority Interest in HomeMed, Forging Partnership With East Alabama Health

Rhea-AI Impact
Rhea-AI Sentiment
partnership acquisition
Rhea-AI Summary
Viemed Healthcare, Inc. (NASDAQ:VMD) finalizes a strategic partnership with East Alabama Health, acquiring controlling interest in HomeMed. The collaboration aims to enhance home medical equipment services in Eastern Alabama, marking a significant milestone in Viemed's growth strategy.
  • None.
  • None.

The strategic partnership between Viemed Healthcare and East Alabama Health, culminating in the acquisition of a controlling interest in East Alabama HomeMed, LLC, represents a notable development in the healthcare services industry. This transaction is indicative of a growing trend where healthcare providers are seeking to expand their service offerings through strategic collaborations.

From a market perspective, the integration of home medical equipment services within Viemed's portfolio could potentially streamline patient care and improve outcomes, which in turn may enhance customer loyalty and brand reputation. The estimated incremental annualized revenue of $4 million signals a positive financial trajectory for Viemed, though it is essential to monitor how this projection aligns with actual performance post-acquisition.

Furthermore, the scalability of this partnership model could serve as a catalyst for similar deals in the future, potentially reshaping the competitive landscape. It will be important to observe how Viemed leverages this partnership to optimize operational efficiencies and whether they can indeed replicate this blueprint nationwide as intended.

Viemed's acquisition of a majority stake in HomeMed is a strategic move that could have significant implications for the company's financial health. The anticipated $4 million in incremental annualized revenue suggests a positive impact on Viemed's top-line growth. However, investors should consider the cost of acquisition and the integration process when evaluating the potential return on investment.

It is also important to assess the long-term financial benefits, such as cost savings from economies of scale and potential market share gains. The partnership may enable Viemed to negotiate better terms with suppliers and payers, an aspect that could improve profit margins over time. Additionally, the expansion into Eastern Alabama provides a broader geographical footprint, which could serve as a platform for further growth and diversification.

Investors should keep an eye on subsequent quarterly reports to gauge the impact of this transaction on Viemed's financial performance and whether the projected revenue synergies materialize as expected.

The completion of Viemed's strategic partnership with East Alabama Health to take a controlling interest in HomeMed is not just a business transaction but also a legal undertaking that could have regulatory implications. Given the nature of the healthcare industry, compliance with federal and state regulations, including patient privacy laws and healthcare service standards, is paramount.

While the partnership is poised to enhance service delivery, it is essential to ensure that the managerial responsibilities assumed by Viemed adhere to the stringent healthcare regulations. The minority interest retained by EAH could provide continuity and stability, potentially mitigating legal and regulatory risks associated with the transition.

Moreover, as Viemed seeks to replicate this model nationwide, it will be important to navigate the varying legal landscapes across different jurisdictions. The legal expertise will be invaluable in structuring future partnerships to ensure compliance while achieving business objectives.

LAFAYETTE, La., April 02, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, announced the finalization of its strategic partnership with East Alabama Health (“EAH”), providing Viemed with the controlling interest of East Alabama HomeMed, LLC ("HomeMed"). HomeMed provides home medical equipment services to patients within the EAH network as well as those in the surrounding areas of Eastern Alabama.

"We are thrilled to join forces with the exceptional team at East Alabama Health to deliver best-in-class home medical services to their patients and expand HomeMed’s business through the strategic partnership," said Viemed Chief Executive Officer Casey Hoyt. "This marks a significant milestone in our ongoing growth strategy, which includes hospital joint ventures and institutional partnerships. We view this transaction as a blueprint that can be replicated nationwide, enhancing care quality while simultaneously creating value for healthcare systems."

Laura Grill, President and CEO of EAH, emphasized that the collaboration with Viemed aligns seamlessly with East Alabama Health’s organizational mission to provide the best possible care for every patient, every time, and to do so with empathy, kindness and caring. The EAH network encompasses East Alabama Medical Center in Opelika, AL, and EAMC-Lanier Hospital in Valley, AL, with a combined medical staff of 380 physicians.

The transaction closed on April 1, 2024, with Viemed acquiring a majority ownership interest and assuming managerial responsibilities of HomeMed. EAH will retain a minority, non-controlling interest in the entity. Viemed expects incremental annualized revenue from the acquired operations of approximately $4 million.


Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. Visit our website at

For further information, please contact:

Glen Akselrod
Bristol Capital

Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or “forward-looking information” as such term is defined in applicable Canadian securities legislation (collectively, “forward-looking statements”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. All statements other than statements of historical fact, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance, including the Company's ability to expand HomeMed’s business, to replicate the transaction nationwide, and expected annualized revenue associated with the acquisition, are not historical facts and may be forward-looking statements and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking statements to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business, market and economic conditions in the regions in which the Company operates; significant capital requirements and operating risks that the Company may be subject to; the ability of the Company to implement business strategies and pursue business opportunities; volatility in the market price of the Company's common shares; the state of the capital markets; the availability of funds and resources to pursue operations; inflation; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on the Company's information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the Company’s status as an emerging growth company and a smaller reporting company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, and claims resulting from such events or concerns; as well as those risk factors discussed or referred to in the Company’s disclosure documents filed with the U.S. Securities and Exchange Commission (the “SEC”) available on the SEC’s website at, including the Company’s most recent Annual Report on Form 10-K, and with the securities regulatory authorities in certain provinces of Canada available at Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking statements prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking statements are expressly qualified in their entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking statements. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.

The ticker symbol for Viemed Healthcare, Inc. is VMD.

Viemed Healthcare, Inc. announced the finalization of a strategic partnership with East Alabama Health, acquiring controlling interest in HomeMed.

HomeMed provides home medical equipment services to patients within the EAH network and surrounding areas of Eastern Alabama.

The transaction between Viemed Healthcare, Inc. and East Alabama Health closed on April 1, 2024.

Viemed Healthcare, Inc. expects incremental annualized revenue of approximately $4 million from the acquired operations.
Viemed Healthcare Inc


VMD Rankings

VMD Latest News

VMD Stock Data

Dental Laboratories
Health Services, Hospital/Nursing Management, Manufacturing, Dental Laboratories

About VMD

viemed is a respiratory disease management company. our mission is to educate, nurture, and inspire our patients to lead better lives. we accomplish this through a highly effective home treatment model that integrates easily into the processes of our referral partners to effectively transition patients from the hospital to their home or other long-term care setting. while our respiratory care practitioners, trained as copd educators, deliver therapy and counseling to patients in their home utilizing the most effective technology available, our care consultants work with hospitals, aco’s, snf’s and other referral sources to simplify the administrative process of transitioning patients from hospital to home care. we achieve industry leading outcomes in hospital readmissions and patient satisfaction which has resulted in us becoming one of the largest home non-invasive ventilation providers in the usa.